Naomi Dempsey, MD

Articles by Naomi Dempsey, MD

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

August 12th 2024

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

August 5th 2024

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

August 5th 2024

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 29th 2024

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 29th 2024

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 29th 2024

A medical expert navigates toxicity management in patients being treated with ribociclib.

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 29th 2024

Dr. Rugo details her management strategy in regards to GI toxicities.

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 10th 2024

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

ByKirollos S. Hanna, PharmD, BCPS, BCOP,Hope Rugo, MD,Joyce O’Shaughnessy, MD,Naomi Dempsey, MD

July 10th 2024

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Naomi Dempsey, MD

Articles by Naomi Dempsey, MD

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Latest Updated Articles

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Naomi Dempsey, MD

Articles by Naomi Dempsey, MD

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Latest Updated Articles

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor